Dr. Patrick Marcellin stands as a preeminent authority in viral hepatitis research and clinical management with international recognition for his transformative contributions to liver disease treatment. He currently serves as Professor of Hepatology at the University of Paris and directs the Viral Hepatitis Research Unit at Hôpital Beaujon in Clichy, France, a leading institution within the Assistance Publique - Hôpitaux de Paris system. His distinguished career spans several decades during which he has established himself as one of Europe's foremost experts in hepatitis B and C infections. As a senior clinician-scientist, Dr. Marcellin masterfully bridges cutting edge research with direct patient care, maintaining an active clinical practice while leading a major research program that influences global treatment standards.
Dr. Marcellin's seminal contributions to hepatitis B therapeutics have fundamentally reshaped clinical practice worldwide through his extensive research on nucleos(t)ide analogues including tenofovir disoproxil fumarate. His landmark 2009 publication on hepatitis management provided critical insights during a pivotal moment in the field's evolution, helping standardize treatment approaches across multiple healthcare systems globally. As principal investigator of major clinical trials, he has generated essential evidence supporting current international guidelines for chronic hepatitis B infection management. His work extends to hepatitis C as well, where he has significantly contributed to optimizing therapeutic regimens and understanding treatment response mechanisms during the transition to direct-acting antiviral therapies.
Beyond his personal research program, Dr. Marcellin has profoundly influenced global hepatitis policy through leadership roles in major professional organizations including the European Association for the Study of the Liver. He regularly serves on guideline committees that shape international standards for hepatitis diagnosis and management, ensuring research advances translate directly into improved patient outcomes worldwide. As a dedicated educator, he has mentored countless hepatology specialists who now lead programs across Europe and contribute to the field's continued advancement. Currently, his research focuses on optimizing treatment strategies for difficult-to-cure hepatitis cases and developing more effective population-level approaches to hepatitis elimination.
